PCV70 DECISION ANALYSIS AND COSTS OF LOW MOLECULAR WEIGHT HEPARINS: A CASE STUDY IN FRANCE  by Launois, R & Gerlier, L
706 Abstracts
OBJECTIVES: In the LIFE study, losartan-based antihyperten-
sive therapy reduced the primary composite endpoint of cardio-
vascular death, myocardial infarction, or stroke by 13% (p =
0.02) and reduced the risk of stroke by 25% (p = 0.001), despite
comparable degree of blood pressure control in hypertensive
patients with left ventricular hypertension (LVH) over 5.5 years.
The objective of this study was to estimate LIFE target popula-
tion (55–80 years, Diastolic BP /Systolic BP: 95–115/ 160–200
mmHg, ECG-LVH without heart failure or angina pectoris) and
to project the reduction in stroke observed with losartan versus
atenolol-based therapy in the LIFE study in France. METHODS:
The population aged 55–80 was extracted from national statis-
tics. Prevalence of hypertension was estimated by extrapolating
the WHO MONICA data (Lille, Strasbourg, Toulouse) to this
segment of the population. The number of patients with con-
gestive heart failure and/or angina pectoris calculated from
Thales (computerized data base) was substracted. Prevalence of
LVH was based on the LIFE pilot study results. Number of
strokes averted was estimated by multiplying the number of
patients meeting LIFE inclusion criteria by the cumulative inci-
dence risk difference in stroke from LIFE at 5.5 years. RESULTS:
The French population aged 55–80 is comprised of 13 million
people. Half are hypertensive. We conservatively projected that
1.4 million individuals meet LIFE study criteria. Using losartan
based therapy in this target population, the projected cumulative
number of strokes over 5.5 years would be 67,957, compared to
90,147 with atenolol, a difference of stroke averted of 22,190.
CONCLUSIONS: The reduction with a losartan-based vs.
atenolol-based regimen should be viewed as representing an
incremental improvement relative to the beneﬁt of conventional
antihypertensives therapies, betablockers and diuretics. A popu-
lation wide prevention of using losartan in hypertensive patients
with LVH has the potential to have a major public health impact
by reducing stroke incidence in France.
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OBJECTIVES: Despite evidence-based guidelines the use of anti-
coagulation therapy in the prevention of strokes in patients with
nonvalvular atrial ﬁbrillation (AFib) is sub-optimal. The therapy
involves a trade-off between the potential beneﬁts of reducing
the risk of ischemic stroke versus the risk of haemorrhagic bleed-
ing. The aim of the study was to identify and describe physicians’
attitudes and beliefs in the assessment of risks connected with
anti-coagulation treatment. METHODS: A telephone interview
was conducted with a cross-section of GP’s, internists and car-
diologists randomly selected from a sub-set of 7,072 out of the
59,953 ofﬁce-based physicians of these specialities in Germany.
RESULTS: A total of 75 people completed the surveys (15.1%
of 498 eligible respondents). Only 25% of the physicians iden-
tiﬁed the right relative risk-reduction of anticoagulation (INR
2–3) while 52% of the physicians agreed strongly with the state-
ment that intracranial bleeding was more regrettable than
ischemic stroke. This was independent of former experiences
with bleeding complications. However, questioning physicians’
personal risk acceptance, most respondents would choose for
themselves a more effective therapy with higher risks (68%), like
anticoagulation therapy in case of AFib, accepting the risk of
bleeding (48%). Fear of bleeding complications was not inde-
pendent of questions of INR-control. Although 89.3% stressed
the high compliance which is needed for anticoagulation therapy,
only 13.4% of physicians disagreed strongly with the statement
that anticoagulation can be used without problems. CONCLU-
SIONS: Results show general acceptance of anticoagulation
treatment by German ofﬁce-based physicians. However, physi-
cians’ assessment of burden of therapy, like difﬁculty in INR-
control or need for patients’ compliance, leads to reservations
against anticoagulation. Also deﬁcits in knowledge of potential
beneﬁts of anticoagulation may contribute to sub-optimal usage
patterns.
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OBJECTIVES: The aim of the study was to emphasize the neces-
sity of deﬁning the market when estimating the cost of two drugs.
One can appear cheaper than another when only a certain part
of the market is considered, and becoming the most expensive
after all societal costs have been taken into account. METHODS:
We focused on the sales of two widespread Low Molecular
Weight Heparins (LMWH) in France from an ambulatory point
of view. We then added the number of syringes distributed in
hospitals, and compared the new costs obtained. A decision tree
with market shares as probabilities made the calculation of
weighted mean costs particularly clear. RESULTS: When only
syringes sold by an ambulatory were considered, the daily cost
of enoxaparine preventive dosages was 31% more expensive
than that of tinzaparine (4.77€ vs. 3.63€). There was a 21% dif-
ference for curative dosages (13.18€ vs. 10.85€). When all the
sold syringes -hospital and open care- have been integrated in
the calculation of mean costs, the conclusion was completely
opposite: the daily cost for tinzaparine was 90% more expensive
than that of enoxaparine on preventive dosages (3.62€ vs.
1.91€). For curative dosages, tinzaparine daily cost reaches more
than twice the enoxaparine daily cost (10.09€ vs. 4.62€). Global
weighted daily costs of enoxaparine and tinzaparine regardless
of indication and market are respectively 2.18€ and 6.21€. CON-
CLUSIONS: The segmentation of the health care system and the
practice of different prices according to the type of markets
(ambulatory, hospital) prevent the public decision-makers to
have a clear view of the real cost of the drugs from a societal
viewpoint.
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OBJECTIVES: To assess the effects of increasing the statin
potency in the management of hypercholesterolemia in general
practice and cardiology outpatient settings in Germany.
METHODS: A total of 603 randomly drawn patients from 
62 selected general and cardiology practices in Germany. All
patients had established coronary heart disease, initiated on
lipid-lowering therapy (LLT) between July 1, 1998 and June 30,
1999, had at least one LDL-C measurement in the preceding year
and were treated for secondary prevention for at least two years
(or until the patient’s death) after LLT initiation. Out of 603
patients, 153 had a ﬁnal switch to a higher potency statin (either
the same statin or a different one) and are analyzed here.
RESULTS: The 153 patients had a mean baseline LDL-C 
of 170.8mg/dL, mean age of 63 years, mean baseline TC of
